197 related articles for article (PubMed ID: 22571665)
1. Cyclin-dependent kinase inhibitors inspired by roscovitine: purine bioisosteres.
Jorda R; Paruch K; Krystof V
Curr Pharm Des; 2012; 18(20):2974-80. PubMed ID: 22571665
[TBL] [Abstract][Full Text] [Related]
2. Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity.
Jorda R; Havlícek L; McNae IW; Walkinshaw MD; Voller J; Sturc A; Navrátilová J; Kuzma M; Mistrík M; Bártek J; Strnad M; Krystof V
J Med Chem; 2011 Apr; 54(8):2980-93. PubMed ID: 21417417
[TBL] [Abstract][Full Text] [Related]
3. Biaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part I.
Trova MP; Barnes KD; Barford C; Benanti T; Bielaska M; Burry L; Lehman JM; Murphy C; O'Grady H; Peace D; Salamone S; Smith J; Snider P; Toporowski J; Tregay S; Wilson A; Wyle M; Zheng X; Friedrich TD
Bioorg Med Chem Lett; 2009 Dec; 19(23):6608-12. PubMed ID: 19846305
[TBL] [Abstract][Full Text] [Related]
4. Pyrazolo[1,5-a]-1,3,5-triazine as a purine bioisostere: access to potent cyclin-dependent kinase inhibitor (R)-roscovitine analogue.
Popowycz F; Fournet G; Schneider C; Bettayeb K; Ferandin Y; Lamigeon C; Tirado OM; Mateo-Lozano S; Notario V; Colas P; Bernard P; Meijer L; Joseph B
J Med Chem; 2009 Feb; 52(3):655-63. PubMed ID: 19128055
[TBL] [Abstract][Full Text] [Related]
5. Heterobiaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part II.
Trova MP; Barnes KD; Alicea L; Benanti T; Bielaska M; Bilotta J; Bliss B; Duong TN; Haydar S; Herr RJ; Hui Y; Johnson M; Lehman JM; Peace D; Rainka M; Snider P; Salamone S; Tregay S; Zheng X; Friedrich TD
Bioorg Med Chem Lett; 2009 Dec; 19(23):6613-7. PubMed ID: 19854650
[TBL] [Abstract][Full Text] [Related]
6. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases.
Bettayeb K; Oumata N; Echalier A; Ferandin Y; Endicott JA; Galons H; Meijer L
Oncogene; 2008 Oct; 27(44):5797-807. PubMed ID: 18574471
[TBL] [Abstract][Full Text] [Related]
7. 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
Vymětalová L; Havlíček L; Šturc A; Skrášková Z; Jorda R; Pospíšil T; Strnad M; Kryštof V
Eur J Med Chem; 2016 Mar; 110():291-301. PubMed ID: 26851505
[TBL] [Abstract][Full Text] [Related]
8. Structural Basis of the Interaction of Cyclin-Dependent Kinase 2 with Roscovitine and Its Analogues Having Bioisosteric Central Heterocycles.
Nekardová M; Vymětalová L; Khirsariya P; Kováčová S; Hylsová M; Jorda R; Kryštof V; Fanfrlík J; Hobza P; Paruch K
Chemphyschem; 2017 Apr; 18(7):785-795. PubMed ID: 28128514
[TBL] [Abstract][Full Text] [Related]
9. 8-Azapurines as new inhibitors of cyclin-dependent kinases.
Havlicek L; Fuksova K; Krystof V; Orsag M; Vojtesek B; Strnad M
Bioorg Med Chem; 2005 Sep; 13(18):5399-407. PubMed ID: 15993080
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.
N'gompaza-Diarra J; Bettayeb K; Gresh N; Meijer L; Oumata N
Eur J Med Chem; 2012 Oct; 56():210-6. PubMed ID: 22982525
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases.
Zatloukal M; Jorda R; Gucký T; Řezníčková E; Voller J; Pospíšil T; Malínková V; Adamcová H; Kryštof V; Strnad M
Eur J Med Chem; 2013 Mar; 61():61-72. PubMed ID: 22770608
[TBL] [Abstract][Full Text] [Related]
12. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors.
Wilson SC; Atrash B; Barlow C; Eccles S; Fischer PM; Hayes A; Kelland L; Jackson W; Jarman M; Mirza A; Moreno J; Nutley BP; Raynaud FI; Sheldrake P; Walton M; Westwood R; Whittaker S; Workman P; McDonald E
Bioorg Med Chem; 2011 Nov; 19(22):6949-65. PubMed ID: 21982796
[TBL] [Abstract][Full Text] [Related]
14. Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1.
Oumata N; Bettayeb K; Ferandin Y; Demange L; Lopez-Giral A; Goddard ML; Myrianthopoulos V; Mikros E; Flajolet M; Greengard P; Meijer L; Galons H
J Med Chem; 2008 Sep; 51(17):5229-42. PubMed ID: 18698753
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluations of pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 inhibitors.
Kim DC; Lee YR; Yang BS; Shin KJ; Kim DJ; Chung BY; Yoo KH
Eur J Med Chem; 2003 May; 38(5):525-32. PubMed ID: 12767603
[TBL] [Abstract][Full Text] [Related]
16. Several human cyclin-dependent kinase inhibitors, structurally related to roscovitine, are new anti-malarial agents.
Houzé S; Hoang NT; Lozach O; Le Bras J; Meijer L; Galons H; Demange L
Molecules; 2014 Sep; 19(9):15237-57. PubMed ID: 25251193
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
De Azevedo WF; Leclerc S; Meijer L; Havlicek L; Strnad M; Kim SH
Eur J Biochem; 1997 Jan; 243(1-2):518-26. PubMed ID: 9030780
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases.
Liebl J; Krystof V; Vereb G; Takács L; Strnad M; Pechan P; Havlicek L; Zatloukal M; Fürst R; Vollmar AM; Zahler S
Angiogenesis; 2011 Sep; 14(3):281-91. PubMed ID: 21487803
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of guanidino analogues of roscovitine.
Dolečková I; Cesnek M; Dračinský M; Brynda J; Voller J; Janeba Z; Kryštof V
Eur J Med Chem; 2013 Apr; 62():443-52. PubMed ID: 23399722
[TBL] [Abstract][Full Text] [Related]
20. Roscovitine-based CDK inhibitors acting as N-donor ligands in the platinum(II) oxalato complexes: preparation, characterization and in vitro cytotoxicity.
Trávnícek Z; Starha P; Popa I; Vrzal R; Dvorák Z
Eur J Med Chem; 2010 Oct; 45(10):4609-14. PubMed ID: 20692737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
